Towa Pharmaceutical Co., Ltd. (TYO:4553)

Revenue by Segment

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Unallocated Adjustment Amount	-895.00M	-374.00M	-105.00M	-166.00M	-
Domestic	216.98B	206.10B	178.72B	155.54B	126.68B
Domestic Growth	5.28%	15.32%	14.90%	22.78%	-
Overseas	57.63B	53.87B	49.32B	53.49B	38.94B
Overseas Growth	6.99%	9.21%	-7.78%	37.36%	-
Total	273.71B	259.59B	227.93B	208.86B	165.61B
Total Growth	5.44%	13.89%	9.13%	26.11%	6.92%

Revenue by Geography

Financials in millions JPY. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020	Mar 31, 2019	Mar 31, 2018	Mar 31, 2017
Overseas	67.39B	64.15B	58.71B	61.90B	39.01B
Overseas Growth	5.04%	9.27%	-5.16%	58.68%	7.72%
Japan	206.32B	195.44B	169.23B	146.96B	126.60B
Japan Growth	5.57%	15.49%	15.15%	16.08%	6.67%
Total	273.71B	259.59B	227.93B	208.86B	165.62B
Total Growth	5.44%	13.89%	9.13%	26.11%	6.92%

Data Source: S&P Global Market Intelligence Last updated: Mar 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Jul 10, 2026

Data Sources Report a data error